Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience.
- Author:
Jeongseok KIM
1
;
Dok Hyun YOON
;
Inkeun PARK
;
Shin KIM
;
Jung Sun PARK
;
Sang Wook LEE
;
Jooryung HUH
;
Chan Sik PARK
;
Cheolwon SUH
Author Information
- Publication Type:Original Article
- Keywords: Diffuse large B cell lymphoma; Intrathecal prophylaxis; Primary testicular lymphoma
- MeSH: Central Nervous System; Diagnosis; Disease-Free Survival; Drug Therapy*; Follow-Up Studies; Humans; Lymphoma; Lymphoma, B-Cell*; Medical Records; Orchiectomy; Radiotherapy; Recurrence; Retrospective Studies; Testis
- From:Blood Research 2014;49(3):170-176
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Primary testicular diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive extranodal lymphoma, and its relapse in the central nervous system (CNS) is a major concern during treatment. Despite this, the role of intrathecal prophylaxis in primary testicular DLBCL remains controversial. METHODS: We retrospectively reviewed the medical records of 14 patients with primary testicular DLBCL diagnosed between November 2000 and June 2012, and analyzed the CNS relapse rate in patients treated without intrathecal prophylaxis. Survival curves were estimated using the Kaplan-Meier method. RESULTS: The median age at diagnosis was 57 years (range, 41-79 years). Unilateral testicular involvement was observed in 13 patients. Nine patients had stage I, 1 had stage II, and 4 had stage IV disease. The international prognostic index was low or low-intermediate risk in 12 patients and high-intermediate risk in 2 patients. Thirteen patients underwent orchiectomy. All the patients received systemic chemotherapy without intrathecal prophylaxis, and prophylactic radiotherapy was administered to the contralateral testis in 12 patients. The median follow-up period of surviving patients was 39 months (range, 10-139 months). Median overall survival was not reached and the median progression-free survival was 3.8 years. Four patients experienced relapse, but CNS relapse was observed in only one patient (7.1%) with stage IV disease, 27 months after a complete response. CONCLUSION: Even without intrathecal prophylaxis, the rate of relapse in the CNS was lower in the Korean patients with primary testicular DLBCL compared to prior reports.
